Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + MET mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EGFR-RAD51 fusion (5)

HLA-DRB1-MET fusion (3)

EGFR-SEPTIN14 fusion (2)

KIF5B-MET fusion (2)

MET-ATXN7L1 fusion (2)

EGFR fusion (1)

EGFR-GRB2 fusion (1)

KIF5B-EGFR fusion (1)

CD47-MET fusion (1)

EHBP1‐MET fusion (1)

KIF5B-MET fusion + MET-CDR2 fusion (1)

MET-TNS3 fusion (1)

MET-TRIM4 fusion (1)

MET-UBE2H fusion (1)

PRKAR1A-MET fusion (1)

RBPMS-MET fusion (1)

STARD3NL-MET fusion (1)

EGFR fusion + RAD51 fusion (0)

EGFR-RAD51 fusion (5)

HLA-DRB1-MET fusion (3)

EGFR-SEPTIN14 fusion (2)

KIF5B-MET fusion (2)

MET-ATXN7L1 fusion (2)

EGFR fusion (1)

EGFR-GRB2 fusion (1)

KIF5B-EGFR fusion (1)

CD47-MET fusion (1)

EHBP1‐MET fusion (1)

KIF5B-MET fusion + MET-CDR2 fusion (1)

MET-TNS3 fusion (1)

MET-TRIM4 fusion (1)

MET-UBE2H fusion (1)

PRKAR1A-MET fusion (1)

RBPMS-MET fusion (1)

STARD3NL-MET fusion (1)

EGFR fusion + RAD51 fusion (0)

›

EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR mutation + MET mutation	Non Small Cell Lung Cancer	EGFR mutation + MET mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3	osimertinib + savolitinib Sensitive: C3 – Early Trials osimertinib + savolitinib Sensitive : C3